Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer
Rie Furukawa(Kyushu University), Isamu Okamoto(Kyushu University Hospital)
Cited by 25
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with <i>EGFR</i> Mutations
|Clinical Cancer Research|2009|189
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer
|Clinical Cancer Research|2012|156
The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer
|Oncogene|2013|143
Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non–Small Cell Lung Cancer
|Journal of Thoracic Oncology|2018|38